Table 1.
Demographics and baseline clinical features of the study population based upon etiology.
| ALI* | ALF | |||||
|---|---|---|---|---|---|---|
| N | Non-APAP (N=41) | APAP (N=49) | N | Non-APAP (N=50) | APAP (N=49) | |
| Age (yrs) | 90 | 48.0±26.0 | 33.0±19.0 | 99 | 52.0±22.2 | 38.0±19.0 |
| Gender (% Female) | 90 | 18(43.9) | 34(69.4) | 99 | 25(50.0) | 31(63.3) |
| Race (% White) | 90 | 27(65.9) | 36(73.5) | 99 | 40(80.0) | 46(93.9) |
| INR | 87 | 2.4±1.0 | 3.1±1.9 | 94 | 3.1±2.6 | 3.4±3.0 |
| Platelet (x109/L) | 85 | 173.0±91.0 | 149.5±74.0 | 95 | 118.0±138.0 | 126.5±87.8 |
| Bilirubin (mg/dl) | 89 | 10.8±9.7 | 2.7±2.8 | 94 | 7.4±13.4 | 4.5±4.4 |
| Creatinine (mg/dl) | 88 | 1.0±1.0 | 0.9±0.5 | 98 | 2.1±2.0 | 1.7±1.9 |
| Fibrinogen (mg/dl) | 23 | 190.0±91.0 | 200.0±73.2 | 44 | 172.0±103.0 | 177.0±133.0 |
| aPTT (sec) | 41 | 44.0±16.1 | 32.1±6.0 | 70 | 42.7±20.9 | 33.7±17.9 |
| RRT at Admission (%) | 90 | 0(0.0) | 2(4.1) | 99 | 17(34.0) | 16(32.7) |
| Hepatic Encephalopathy (% grade 3/4) | 96 | 26(54.2) | 26(54.2) | |||
| SIRS (Present) | 35 | 6(60.0) | 12(48.0) | 75 | 28(77.8) | 30(76.9) |
APAP, acetaminophen; RRT, renal replacement therapy; SIRS, systemic inflammatory response syndrome.
*
Ten patients (4 APAP and 6 non-APAP) presented as ALI but developed hepatic encephalopathy (ALF) during the study (“converters”); one ALI patient had liver injury of unknown etiology. Baseline data of these patients were omitted from this table.